Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Accured Expenses (2016 - 2025)

Apyx Medical (APYX) has disclosed Change in Accured Expenses for 15 consecutive years, with $553000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 528.41% year-over-year to $553000.0, compared with a TTM value of $209000.0 through Dec 2025, up 109.22%, and an annual FY2025 reading of $209000.0, up 109.22% over the prior year.
  • Change in Accured Expenses was $553000.0 for Q4 2025 at Apyx Medical, up from $79000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.8 million in Q3 2022 and bottomed at -$1.8 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is $21368.4, with a median of $79000.0 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses surged 1046.85% in 2021, then tumbled 2447.76% in 2024.
  • Year by year, Change in Accured Expenses stood at $1.8 million in 2021, then plummeted by 167.45% to -$1.2 million in 2022, then soared by 218.29% to $1.4 million in 2023, then crashed by 93.84% to $88000.0 in 2024, then soared by 528.41% to $553000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for APYX at $553000.0 in Q4 2025, $79000.0 in Q3 2025, and $433000.0 in Q2 2025.